Compare BGI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGI | LSTA |
|---|---|---|
| Founded | 1879 | 1980 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 20.9M |
| IPO Year | 2005 | N/A |
| Metric | BGI | LSTA |
|---|---|---|
| Price | $1.09 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 23.7K | ★ 27.3K |
| Earning Date | 12-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $136,846,182.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $0.56 | $1.81 |
| 52 Week High | $2.03 | $4.20 |
| Indicator | BGI | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 38.85 |
| Support Level | $1.00 | $1.85 |
| Resistance Level | $1.11 | $2.09 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 93.34 | 36.81 |
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.